Comparison of Growth Factor Releases and Degradation Rates of Membranes Obtained From A-PRF+, L-PRF, and Alb-PRF
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- VEGF concentration released from PRF membranes
研究概览
简要总结
Platelet-rich fibrin (PRF) is widely used in regenerative dentistry because of its autologous growth factor release and fibrin scaffold properties. Different PRF preparations may exhibit different biological characteristics that influence their clinical performance. This study aims to compare Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) regarding cumulative growth factor release and fibrin degradation. Blood samples obtained from healthy volunteers will be processed to prepare all three PRF types. Growth factor release and fibrin degradation will be analyzed under standardized laboratory conditions.
详细描述
Platelet-rich fibrin products have become increasingly popular in regenerative medicine because they provide a fibrin scaffold capable of releasing multiple growth factors over time. However, differences in centrifugation protocols and preparation techniques may significantly affect their biological properties.
Albumin-PRF is a recently introduced modification that combines heat-denatured plasma proteins with injectable PRF to increase scaffold stability and prolong growth factor release.
This study will compare Alb-PRF, A-PRF+, and L-PRF prepared from the same healthy volunteers. Cumulative release of VEGF, PDGF-BB, and TGF-β1 will be evaluated on Days 1, 3, 5, and 7 using ELISA. Resistance to enzymatic degradation will be assessed by measuring delta D-dimer concentrations following trypsin-EDTA exposure. The results are expected to improve understanding of the biological performance of different PRF formulations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Single (Outcomes Assessor)
盲法说明
Samples were coded before laboratory analyses. The researcher performing the ELISA and D-dimer measurements was unaware of the PRF preparation assigned to each sample until the analyses were completed.
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers aged 18 to 40 years
- •Male or female
- •Able and willing to provide written informed consent
- •Non-smokers
- •No history of systemic disease
- •No regular medication use
- •No use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months
排除标准
- •Age younger than 18 years or older than 40 years
- •Pregnancy or breastfeeding
- •History of any systemic disease
- •Regular medication use
- •Use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months
- •Refusal or inability to provide written informed consent
研究组 & 干预措施
Albumin-Platelet Rich Fibrin (Alb-PRF)
Blood samples obtained from healthy volunteers were processed using the Albumin-Platelet Rich Fibrin (Alb-PRF) protocol. Growth factor release and resistance to enzymatic degradation were evaluated under standardized laboratory conditions.
干预措施: Albumin-Platelet Rich Fibrin (Alb-PRF) (Biological)
Leukocyte-Platelet Rich Fibrin (L-PRF)
Blood samples obtained from healthy volunteers were processed using the Leukocyte-Platelet Rich Fibrin (L-PRF) protocol. Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Advanced Platelet-Rich Fibrin+ (A-PRF+).
干预措施: Leukocyte-Platelet Rich Fibrin (L-PRF) (Biological)
Advanced - Platelet Rich Fibrin+ (A-PRF+)
Blood samples obtained from healthy volunteers were processed using the Advanced Platelet-Rich Fibrin+ (A-PRF+) protocol. Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Leukocyte-Platelet Rich Fibrin (L-PRF) .
干预措施: Advanced Platelet-Rich Fibrin (A-PRF) (Biological)
结局指标
主要结局
VEGF concentration released from PRF membranes
时间窗: Day 1, Day 3, Day 5, and Day 7
Quantitative assessment of VEGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
PDGF concentration released from PRF membranes
时间窗: Day 1, Day 3, Day 5, and Day 7
Quantitative assessment of PDGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
TGF-B concentration released from PRF membranes
时间窗: Day 1, Day 3, Day 5, and Day 7
Quantitative assessment of TGF-B released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Resistance to enzymatic degradation
时间窗: 60 minutes and 120 minutes
Assessment of fibrin degradation by measuring D-dimer levels after enzymatic digestion of PRF preparations.
次要结局
未报告次要终点
研究者
Hülya Anak
Dentist
Izmir Katip Celebi University